๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Singapore
Clinical trial register · Singapore

Clinical Trials in Singapore

Every study on the ClinicalTrials.gov registry that lists a site in Singapore and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 948 matching records held by the registry are in this view. Synced 30 Sep 2026, 03:16 UTC
948
Studies in scope
all four open statuses
487
Recruiting now
open to new participants
153
Lead sponsors
across recruiting studies
Top sites
Singapore 60
Narrow the registerReset
Recruitment status
Phase
Site location
Singapore60
All 1 locations
Target enrolment
to

Trials in this register

60 of 948 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Singapore
Start
Recruiting
A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)
NCT07681271Papulopustular Rosacea
Novartis Pharmaceuticals
Phase 2
100
Singapore
2026-07-30
Recruiting
Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab
NCT07039422Primary Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia
Novartis Pharmaceuticals
Phase 2
60
Singapore
2026-06-26
Recruiting
A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
NCT07564401Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Novartis Pharmaceuticals
Phase 1/2
80
Singapore
2026-06-16
Recruiting
Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer
NCT07604571Advanced HR+/HER2- Breast Cancer
Novartis Pharmaceuticals
Phase 1
194
Singapore
2026-05-28
Recruiting
An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.
NCT07543120Hypertension (HTN)
DrugQCZ484
Novartis Pharmaceuticals
Phase 2
323
Singapore
2026-05-07
Recruiting
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
NCT07288359Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
Novartis Pharmaceuticals
Phase 1/2
205
Singapore
2025-12-29
Recruiting
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
NCT07261631Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer
Novartis Pharmaceuticals
Phase 1
180
Singapore
2025-11-24
Active, closed
Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT07220577Atopic Dermatitis
DrugGIA632
Novartis Pharmaceuticals
Phase 2
34
Singapore
2025-11-10
Recruiting
A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation
NCT07217067Atrial Fibrillation
Novartis Pharmaceuticals
Phase 2
165
Singapore
2025-10-28
Active, closed
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
NCT06991556Metastatic Hormone-sensitive Prostate Cancer
Novartis Pharmaceuticals
Phase 2
168
Singapore
2025-07-07
Active, closed
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT07047118Prostatic Cancer, Castration-Resistant
Novartis Pharmaceuticals
Phase 2
138
Singapore
2025-07-03
Recruiting
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
NCT06855277Prostate Cancer
DrugsAAA817·ARPI
Novartis Pharmaceuticals
Phase 3
940
Singapore
2025-07-01
Active, closed
A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease
NCT07048197Rheumatoid Arthritis (RA) and Sjรถgren's Disease (SjD)
Novartis Pharmaceuticals
Phase 1/2
27
Singapore
2025-06-20
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
Novartis Pharmaceuticals
Phase 1/2
280
Singapore
2025-04-03
Active, closed
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
NCT06857955Hypertension
DrugQCZ484
Novartis Pharmaceuticals
Phase 2
396
Singapore
2025-03-26
Active, closed
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
NCT06868290ANCA Associated Vasculitis (AAV)
Novartis Pharmaceuticals
Phase 2
126
Singapore
2025-03-13
Active, closed
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256Idiopathic Inflammatory Myopathies
Novartis Pharmaceuticals
Phase 2
21
Singapore
2024-12-17
Active, closed
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
NCT06655896Scleroderma, Diffuse
Novartis Pharmaceuticals
Phase 2
96
Singapore
2024-10-29
Active, closed
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
NCT06581198Lupus Erythematosus, Systemic, Lupus Nephritis
Novartis Pharmaceuticals
Phase 2
179
Singapore
2024-09-04
Recruiting
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
NCT05939414Oligometastatic Prostate Cancer (OMPC)
Novartis Pharmaceuticals
Phase 3
450
Singapore
2024-03-12
Recruiting
A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever
NCT06006559Dengue
Novartis Pharmaceuticals
Phase 2
108
Singapore
2024-02-20
Active, closed
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
NCT05849298Prostatic Neoplasm
Novartis Pharmaceuticals
Phase 2
49
Singapore
2024-01-03
Active, closed
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
NCT05976243Chronic Inducible Urticaria
Novartis Pharmaceuticals
Phase 3
362
Singapore
2023-12-07
Active, closed
A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma
NCT05888493Follicular Lymphoma (FL)
Novartis Pharmaceuticals
Phase 3
109
Singapore
2023-10-02
Active, closed
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
NCT05838768MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
Novartis Pharmaceuticals
Phase 1
123
Singapore
2023-06-27
Active, closed
Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases
NCT05552469Myeloid Diseases
Novartis Pharmaceuticals
Phase 1
71
Singapore
2023-05-08
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals
Phase 3
14,012
Singapore
2023-03-09
Active, closed
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
NCT05653349Primary Immune Thrombocytopenia (ITP)
Novartis Pharmaceuticals
Phase 3
226
Singapore
2023-02-03
Active, closed
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
NCT05653219Primary Immune Thrombocytopenia
Novartis Pharmaceuticals
Phase 3
152
Singapore
2023-02-02
Active, closed
A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia
NCT05648968Warm Autoimmune Hemolytic Anemia (wAIHA)
Novartis Pharmaceuticals
Phase 3
90
Singapore
2022-12-30
Active, closed
Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials
NCT05335876Spinal Muscular Atrophy (SMA)
Novartis Pharmaceuticals
Phase 3
20
Singapore
2022-12-19
Active, closed
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
NCT05544929Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial
Novartis Pharmaceuticals
Phase 1
126
Singapore
2022-10-26
Active, closed
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT05358249KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
Novartis Pharmaceuticals
Phase 1/2
74
Singapore
2022-10-24
Active, closed
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
NCT05397496B-cell Non-Hodgkin Lymphoma (B-NHL), B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugPIT565
Novartis Pharmaceuticals
Phase 1
61
Singapore
2022-10-03
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Novartis Pharmaceuticals
Phase 4
347
Singapore
2022-08-30
Recruiting
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
NCT05268289Lupus Nephritis
Novartis Pharmaceuticals
Phase 2
240
Singapore
2022-08-10
Active, closed
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
NCT05126277Lupus Nephritis
Novartis Pharmaceuticals
Phase 3
452
Singapore
2022-07-14
Active, closed
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
NCT05142696Extensive Stage Small Cell Lung Cancer
Novartis Pharmaceuticals
Phase 1/2
55
Singapore
2022-07-13
Active, closed
Roll-over Study to Allow Continued Access to Ribociclib
NCT05161195Metastatic Breast Cancer
Novartis Pharmaceuticals
Phase 4
134
Singapore
2022-07-07
Active, closed
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
NCT05030428Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals
Phase 3
17,004
Singapore
2021-11-23
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Novartis Pharmaceuticals
Phase 3
405
Singapore
2021-10-06
Active, closed
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
NCT04557462Primary IgA Nephropathy
Novartis Pharmaceuticals
Phase 3
448
Singapore
2021-09-20
Active, closed
Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT04747613Paroxysmal Nocturnal Hemoglobinuria
Novartis Pharmaceuticals
Phase 3
208
Singapore
2021-07-27
Active, closed
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT04699188KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
Novartis Pharmaceuticals
Phase 1/2
344
Singapore
2021-02-24
Active, closed
Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC
NCT03333343EGFR-mutant Non-small Cell Lung Cancer
Novartis Pharmaceuticals
Phase 1
105
Singapore
2018-01-29
Active, closed
Ribociclib (LEE011) Rollover Study for Continued Access
NCT02934568Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies
Novartis Pharmaceuticals
Phase 2
22
Singapore
2016-12-15
Active, closed
Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
NCT02584933ALK Positive Malignancies
Novartis Pharmaceuticals
Phase 4
233
Singapore
2015-12-11
Recruiting
CAR-T Long Term Follow Up (LTFU) Study
NCT02445222Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Novartis Pharmaceuticals
Phase 3
1,400
Singapore
2015-11-02
Active, closed
Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer
NCT02393625ALK-positive NSCLC
Novartis Pharmaceuticals
Phase 1
57
Singapore
2015-05-27
Active, closed
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
NCT02381886Advanced Malignancies That Harbor IDHR132 Mutations
Novartis Pharmaceuticals
Phase 1
166
Singapore
2015-03-06
Rows per page Showing 1–60 of 60
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Singaporean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 1 October 2026. https://priyalifescience.com/clinical-trials-singapore

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Singapore and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 948 studies in total at the last sync on 30 Sep 2026, 03:16 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 60 of those studies that match the filters currently applied.

How many clinical trials are recruiting in Singapore?

18 of the 60 studies on this page are recruiting new participants as of the 30 Sep 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 42 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase, 60 studies
PhaseStudiesRecruitingShare
Phase 321435%
Phase 217628.3%
Phase 19215%
Phase 1/29415%
Phase 4315%
Phase 2/3111.7%

Most active sponsors

Lead sponsors with the most studies
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals6018

This register, in your inbox every Friday

One email a week with how many trials are recruiting in Ireland, new EMA and FDA approvals and medicine shortages, built from the same public registers as this page.

Free. Unsubscribe from any email with one click. See our privacy policy.

→

Browse trials by condition

Lupus Nephritis (4) Advanced HR+/HER2- Breast Cancer (3) Carcinoma, Non-Small-Cell Lung (3) Non-Small Cell Lung Cancer (2) Primary Immune Thrombocytopenia (2) KRAS G12C Mutant Solid Tumors (2) Advanced CCNE1-amplified Solid Tumors (2) Prostate Cancer (2) Lupus Erythematosus, Systemic (1) Atherosclerotic Cardiovascular Disease (1) Paroxysmal Nocturnal Hemoglobinuria (1) Metastatic Hormone-sensitive Prostate Cancer (1) Idiopathic Inflammatory Myopathies (1) Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program (1) Extensive-stage Small Cell Lung Cancer (ES-SCLC) (1)
→

Browse trials by site location

Singapore (60)
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.